Cargando…
A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform
Obesity is one of the most common global health problems for all age groups with obese people at risk of a variety of associated health complications. Consequently, there is a need to develop new therapies that lower body fat without the side effects. However, obesity is a complex and systemic disea...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399480/ https://www.ncbi.nlm.nih.gov/pubmed/36033279 http://dx.doi.org/10.1016/j.heliyon.2022.e10108 |
_version_ | 1784772531100581888 |
---|---|
author | Haerkens, Freek Kikken, Charlotte Kirkels, Laurens van Amstel, Monique Wouters, Willemijn van Doornmalen, Els Francke, Christof Hughes, Samantha |
author_facet | Haerkens, Freek Kikken, Charlotte Kirkels, Laurens van Amstel, Monique Wouters, Willemijn van Doornmalen, Els Francke, Christof Hughes, Samantha |
author_sort | Haerkens, Freek |
collection | PubMed |
description | Obesity is one of the most common global health problems for all age groups with obese people at risk of a variety of associated health complications. Consequently, there is a need to develop new therapies that lower body fat without the side effects. However, obesity is a complex and systemic disease, so that in vitro results are not easily translatable to clinical situations. A promising way to circumnavigate these issues is to reposition already approved drugs for new treatments, enabling a more streamlined drug discovery process due to the availability of pre-existing pharmacological and toxicological datasets. Chemical libraries, such as the Prestwick Chemical Library of 1200 FDA approved drugs, are available for this purpose. We have developed a simple semi-automated whole-organism approach to screening the Prestwick Chemical Library for those compounds which reduce fat content using the model organism Caenorhabditis elegans. Our whole-organism approach to high-throughput screening identified 9 “lead” compounds that reduced fat within 2 weeks in the model. Further screening and analysis provided 4 “hit” compounds (Midodrine, Vinpocetine, Fenoprofen and Lamivudine) that showed significant promise as drugs to reduce fat levels. The effects of these candidates were found to further reduce fat content in nematodes where an nhr-49/PPAR mutation resulted in “overweight” worms. Upon unblinding the “hit” compounds, they were found to have recently been shown to have anti-obesity effects in mammalian models too. In developing a whole-animal chemical screen to identify pharmacological agents as potential anti-obesity compounds, we demonstrate how chemical libraries can be rapidly and relatively cheaply profiled for active hits. Using the nematode Caenorhabditis elegans thus enables drugs to be assessed for applicability in humans and provides a new incentive to explore drug repurposing as a feasible and efficient way to identify new anti-obesity compounds. |
format | Online Article Text |
id | pubmed-9399480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-93994802022-08-25 A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform Haerkens, Freek Kikken, Charlotte Kirkels, Laurens van Amstel, Monique Wouters, Willemijn van Doornmalen, Els Francke, Christof Hughes, Samantha Heliyon Research Article Obesity is one of the most common global health problems for all age groups with obese people at risk of a variety of associated health complications. Consequently, there is a need to develop new therapies that lower body fat without the side effects. However, obesity is a complex and systemic disease, so that in vitro results are not easily translatable to clinical situations. A promising way to circumnavigate these issues is to reposition already approved drugs for new treatments, enabling a more streamlined drug discovery process due to the availability of pre-existing pharmacological and toxicological datasets. Chemical libraries, such as the Prestwick Chemical Library of 1200 FDA approved drugs, are available for this purpose. We have developed a simple semi-automated whole-organism approach to screening the Prestwick Chemical Library for those compounds which reduce fat content using the model organism Caenorhabditis elegans. Our whole-organism approach to high-throughput screening identified 9 “lead” compounds that reduced fat within 2 weeks in the model. Further screening and analysis provided 4 “hit” compounds (Midodrine, Vinpocetine, Fenoprofen and Lamivudine) that showed significant promise as drugs to reduce fat levels. The effects of these candidates were found to further reduce fat content in nematodes where an nhr-49/PPAR mutation resulted in “overweight” worms. Upon unblinding the “hit” compounds, they were found to have recently been shown to have anti-obesity effects in mammalian models too. In developing a whole-animal chemical screen to identify pharmacological agents as potential anti-obesity compounds, we demonstrate how chemical libraries can be rapidly and relatively cheaply profiled for active hits. Using the nematode Caenorhabditis elegans thus enables drugs to be assessed for applicability in humans and provides a new incentive to explore drug repurposing as a feasible and efficient way to identify new anti-obesity compounds. Elsevier 2022-08-11 /pmc/articles/PMC9399480/ /pubmed/36033279 http://dx.doi.org/10.1016/j.heliyon.2022.e10108 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Haerkens, Freek Kikken, Charlotte Kirkels, Laurens van Amstel, Monique Wouters, Willemijn van Doornmalen, Els Francke, Christof Hughes, Samantha A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform |
title | A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform |
title_full | A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform |
title_fullStr | A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform |
title_full_unstemmed | A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform |
title_short | A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform |
title_sort | new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated caenorhabditis elegans screening platform |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399480/ https://www.ncbi.nlm.nih.gov/pubmed/36033279 http://dx.doi.org/10.1016/j.heliyon.2022.e10108 |
work_keys_str_mv | AT haerkensfreek anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT kikkencharlotte anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT kirkelslaurens anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT vanamstelmonique anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT wouterswillemijn anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT vandoornmalenels anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT franckechristof anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT hughessamantha anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT haerkensfreek newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT kikkencharlotte newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT kirkelslaurens newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT vanamstelmonique newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT wouterswillemijn newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT vandoornmalenels newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT franckechristof newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform AT hughessamantha newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform |